ProfileGDS5678 / 1435504_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 54% 77% 77% 51% 54% 51% 50% 52% 66% 57% 52% 52% 51% 52% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3858354
GSM967853U87-EV human glioblastoma xenograft - Control 25.2283577
GSM967854U87-EV human glioblastoma xenograft - Control 35.1954677
GSM967855U87-EV human glioblastoma xenograft - Control 43.1631151
GSM967856U87-EV human glioblastoma xenograft - Control 53.3048854
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3274751
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.2893550
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.2496952
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.9648766
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4343657
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2504252
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2423252
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.2558151
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.2667752